With a sample size of 6:
After 3 months, 3 out of 6 patients experienced a partial response, a 50% overall response rate(“ORR”) according to immune related response criteria (“irRC”);• The current disease control rate for this group is 66% (4/6);
Seems disappointing.
With a sample size of 18:
ORR of 33% (6/18) was reported according to the protocol when measured from start ofcombination treatment (cycle 5 of pembrolizumab treatment) in patients with suboptimal responseto pembrolizumab monotherapy;
Again, seems disappointing
- Forums
- ASX - By Stock
- IMM
- Ann: Immutep presents new TACTI-mel data at ICI Europe Summit
Ann: Immutep presents new TACTI-mel data at ICI Europe Summit, page-3
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
36.5¢ |
Change
-0.005(1.35%) |
Mkt cap ! $530.2M |
Open | High | Low | Value | Volume |
36.5¢ | 37.0¢ | 35.5¢ | $328.0K | 909.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 38094 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 29559 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 38094 | 0.355 |
8 | 199832 | 0.350 |
4 | 23669 | 0.345 |
3 | 50293 | 0.340 |
4 | 44001 | 0.335 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 29559 | 4 |
0.370 | 132586 | 4 |
0.375 | 59586 | 3 |
0.380 | 79650 | 3 |
0.385 | 101562 | 6 |
Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |